ArticleInternational ophthalmology2026
Outcome of accelerated corneal cross-linking with 0.25% riboflavin in progressive keratoconus patients.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo present the one-year outcomes of accelerated corneal collagen cross-linking (CXL) with 0.25% riboflavin in the management of progressive keratoconus in the East Asian population.
methodsA retrospective analysis was performed on twenty-four patients (32 eyes) diagnosed with progressive keratoconus treated in Taiwan. Exclusion criteria included corneas with a stromal thickness of less than 400 μm. A 15-min soak with 0.25% riboflavin was followed by UVA light exposure at 18 mW/cm
resultsThe mean Kmax decreased from 61.74 ± 9.9 to 60.05 ± 9.1 D at one-year follow-up (P = 0.002). Central corneal pachymetry decreased significantly from 464.16 ± 28.6 to 442.73 ± 87.6 μm (P < 0.001) at one year. The mean demarcation line depth was 375.91 ± 53.4 μm at one-month follow-up. Mean corrected distance visual acuity, manifest refraction and endothelial cell density remained unchanged.
conclusionsOur findings demonstrate the safety and efficacy of accelerated CXL with 0.25% riboflavin for progressive keratoconus, providing an effective option in clinical management.
trial registrationThis study retrospectively registered and approved by the Institutional Review Board (IRB) of the Shin Kong Wu Ho-Su Memorial Hospital. (IRB number: 20240403R).
Indexed as
Identifiers
41848799What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.